Cargando…

Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis

INTRODUCTION: Bladder cancer (BC) is a significant carcinoma of the urinary system that has a high incidence of morbidity and death owing to the challenges in accurately identifying people with early-stage BC and the lack of effective treatment options for those with advanced BC. Thus, there is a ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Weifeng, Huang, Guankai, Lin, Hansen, Ren, Lei, Fu, Liangmin, Mao, Xiaopeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885092/
https://www.ncbi.nlm.nih.gov/pubmed/36727059
http://dx.doi.org/10.3389/fonc.2022.1102392
_version_ 1784879855751397376
author Wang, Weifeng
Huang, Guankai
Lin, Hansen
Ren, Lei
Fu, Liangmin
Mao, Xiaopeng
author_facet Wang, Weifeng
Huang, Guankai
Lin, Hansen
Ren, Lei
Fu, Liangmin
Mao, Xiaopeng
author_sort Wang, Weifeng
collection PubMed
description INTRODUCTION: Bladder cancer (BC) is a significant carcinoma of the urinary system that has a high incidence of morbidity and death owing to the challenges in accurately identifying people with early-stage BC and the lack of effective treatment options for those with advanced BC. Thus, there is a need to define new markers of prognosis and prediction. METHODS: In this study, we have performed a comprehensive proteomics experiment by label-free quantitative proteomics to compare the proteome changes in the serum of normal people and bladder cancer patients—the successful quantification of 2064 Quantifiable proteins in total. A quantitative analysis was conducted to determine the extent of changes in protein species' relative intensity and reproducibility. There were 43 upregulated proteins and 36 downregulated proteins discovered in non-muscle invasive bladder cancer and normal individuals. Sixty-four of these proteins were elevated, and 51 were downregulated in muscle-invasive and non-muscle-invasive bladder cancer, respectively. Functional roles of differentially expressed proteins were annotated using Gene Ontology (GO) and Clusters of Orthologous Groups of Proteins (COG). To analyze the functions and pathways enriched by differentially expressed proteins, GO enrichment analysis, protein domain analysis, and KEGG pathway analysis were performed. The proteome differences were examined and visualized using radar plots, heat maps, bubble plots, and Venn diagrams. RESULTS: As a result of combining the Venn diagram with protein-protein interactions (PPIs), Chloride intracellular channel 1 (CLIC1) was identified as the primary protein. Using the Gene Set Cancer Analysis (GSCA) website, the influence of CLIC1 on immune infiltration was analyzed. A negative correlation between CD8 naive and CLIC1 levels was found. For validation, immunohistochemical (IHC), qPCR, and western blotting (WB) were performed.Further, we found that CLIC1 was associated with a poor prognosis of bladder cancer in survival analysis. DISCUSSION: Our research screened CLIC1 as a tumor-promoting protein in bladder cancer for the first time using serum mass spectrometry. And CLIC1 associated with tumor stage, and immune infiltrate. The prognostic biomarker and therapeutic target CLIC1 may be new for bladder cancer patients.
format Online
Article
Text
id pubmed-9885092
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98850922023-01-31 Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis Wang, Weifeng Huang, Guankai Lin, Hansen Ren, Lei Fu, Liangmin Mao, Xiaopeng Front Oncol Oncology INTRODUCTION: Bladder cancer (BC) is a significant carcinoma of the urinary system that has a high incidence of morbidity and death owing to the challenges in accurately identifying people with early-stage BC and the lack of effective treatment options for those with advanced BC. Thus, there is a need to define new markers of prognosis and prediction. METHODS: In this study, we have performed a comprehensive proteomics experiment by label-free quantitative proteomics to compare the proteome changes in the serum of normal people and bladder cancer patients—the successful quantification of 2064 Quantifiable proteins in total. A quantitative analysis was conducted to determine the extent of changes in protein species' relative intensity and reproducibility. There were 43 upregulated proteins and 36 downregulated proteins discovered in non-muscle invasive bladder cancer and normal individuals. Sixty-four of these proteins were elevated, and 51 were downregulated in muscle-invasive and non-muscle-invasive bladder cancer, respectively. Functional roles of differentially expressed proteins were annotated using Gene Ontology (GO) and Clusters of Orthologous Groups of Proteins (COG). To analyze the functions and pathways enriched by differentially expressed proteins, GO enrichment analysis, protein domain analysis, and KEGG pathway analysis were performed. The proteome differences were examined and visualized using radar plots, heat maps, bubble plots, and Venn diagrams. RESULTS: As a result of combining the Venn diagram with protein-protein interactions (PPIs), Chloride intracellular channel 1 (CLIC1) was identified as the primary protein. Using the Gene Set Cancer Analysis (GSCA) website, the influence of CLIC1 on immune infiltration was analyzed. A negative correlation between CD8 naive and CLIC1 levels was found. For validation, immunohistochemical (IHC), qPCR, and western blotting (WB) were performed.Further, we found that CLIC1 was associated with a poor prognosis of bladder cancer in survival analysis. DISCUSSION: Our research screened CLIC1 as a tumor-promoting protein in bladder cancer for the first time using serum mass spectrometry. And CLIC1 associated with tumor stage, and immune infiltrate. The prognostic biomarker and therapeutic target CLIC1 may be new for bladder cancer patients. Frontiers Media S.A. 2023-01-16 /pmc/articles/PMC9885092/ /pubmed/36727059 http://dx.doi.org/10.3389/fonc.2022.1102392 Text en Copyright © 2023 Wang, Huang, Lin, Ren, Fu and Mao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Wang, Weifeng
Huang, Guankai
Lin, Hansen
Ren, Lei
Fu, Liangmin
Mao, Xiaopeng
Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis
title Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis
title_full Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis
title_fullStr Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis
title_full_unstemmed Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis
title_short Label-free LC-MS/MS proteomics analyses reveal CLIC1 as a predictive biomarker for bladder cancer staging and prognosis
title_sort label-free lc-ms/ms proteomics analyses reveal clic1 as a predictive biomarker for bladder cancer staging and prognosis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885092/
https://www.ncbi.nlm.nih.gov/pubmed/36727059
http://dx.doi.org/10.3389/fonc.2022.1102392
work_keys_str_mv AT wangweifeng labelfreelcmsmsproteomicsanalysesrevealclic1asapredictivebiomarkerforbladdercancerstagingandprognosis
AT huangguankai labelfreelcmsmsproteomicsanalysesrevealclic1asapredictivebiomarkerforbladdercancerstagingandprognosis
AT linhansen labelfreelcmsmsproteomicsanalysesrevealclic1asapredictivebiomarkerforbladdercancerstagingandprognosis
AT renlei labelfreelcmsmsproteomicsanalysesrevealclic1asapredictivebiomarkerforbladdercancerstagingandprognosis
AT fuliangmin labelfreelcmsmsproteomicsanalysesrevealclic1asapredictivebiomarkerforbladdercancerstagingandprognosis
AT maoxiaopeng labelfreelcmsmsproteomicsanalysesrevealclic1asapredictivebiomarkerforbladdercancerstagingandprognosis